Geneva Pharma Network

Calypso Biotech SA

Calypso Biotech SA is a preclinical stage company discovering and developing antibody therapies for severe gastrointestinal diseases. Calypso Biotech SA is a spin-off from Merck-Serono incorporated in 2013 with offices and laboratory within the Eclosion incubator in Plan-les-Ouates and currently has 3 employees.

Additional Info

  • Email This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Contact at GPN Alain Vicari

Independent consultant in the field of Antibody Enginneering

• Provide as a service the design of humanization of mouse / rat antibodies using a modernized version of the traditional CDR grafting technique.
• Provide as a service project plan for antibody projects from discovery to preclinical development and oversee if necessary the progression of the project.
• Due diligence and evaluation of antibody technologies.
• Provide expert advice on broad antibody engineering aspects; especially choice of isotype, affinity maturation, effector function and FcRn binding.

Additional Info

  • Email This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Contact at GPN Olivier Leger

Neuroassets

NeuroAssets is a Neuroscience consulting company working with Pharma, Biotech and Academia on a variety of projects targeting novel therapeutics for brain disorders.  The Company provides strategic guidance and operational management, either for existing companies with such assets, or inventors / entrepreneurs in the creation of start-ups to develop their assets. NeuroAssets also connects innovative neuroscience with financing opportunities.

Additional Info

  • Email This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Contact at GPN Stéphane Genoud